Crossover Pharmacokinetic (PK) Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers
Status:
Completed
Trial end date:
2021-04-05
Target enrollment:
Participant gender:
Summary
Phase 1, open-label, randomized, 3-period, 3-treatment, crossover pharmacokinetic study to
evaluate the steady-state pharmacokinetics of 5 mg/day and 10 mg/day Corplex™ Donepezil TDS
manufactured with the commercial process compared to 10 mg Aricept® in healthy volunteers.